ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$11.34 USD
-0.32 (-2.74%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $11.31 -0.03 (-0.26%) 5:32 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
SPRY 11.34 -0.32(-2.74%)
Will SPRY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray
Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
Other News for SPRY
ARS Pharmaceuticals nasal spray for anaphylaxis endorsed in EU
CHMP endorses ARS nasal spray for anaphylaxis
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
ARS Pharmaceuticals: Corporate Update and EURneffy’s Positive Opinion
ARS Pharmaceuticals: EURneffy recommended for approval by CHMP